Venetoclax
- PDF / 169,111 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 38 Downloads / 172 Views
1 S
Tumour lysis syndrome: case report In a retrospective review, a patient [age and sex not stated] was described, who developed tumour lysis syndrome during treatment with venetoclax for relapsed/refractory chronic lymphocytic leukaemia. The patient, who had relapsed/refractory chronic lymphocytic leukaemia, started receiving venetoclax 20mg daily [route not stated]. The dose was scheduled to increase as quickly as tolerated over a 5-week period to 50mg, 100mg, 200mg and 400mg. Subsequently, the patient developed grade 3 tumour lysis syndrome at an unspecified dose of venetoclax [duration of treatment to reaction onset not stated]. The patient recovered without lasting complications. Koenig K, et al. Rapid dose escalation of venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitor 803446486 therapy. Blood 134 (Suppl. 1): no pagination, Nov 2019 [abstract]
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
